MiniMed Group Inc $MMED Shares Newly Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new stake in MiniMed Group Inc (NASDAQ:MMED) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 159,350 shares of the company’s stock, valued at approximately $3,103,000. Lisanti Capital Growth LLC owned 0.06% of MiniMed Group as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in MMED. Parkside Financial Bank & Trust acquired a new stake in shares of MiniMed Group in the 2nd quarter worth approximately $28,000. Legal & General Group Plc purchased a new position in shares of MiniMed Group in the second quarter valued at $91,000. State of Wyoming acquired a new position in shares of MiniMed Group during the 3rd quarter worth $167,000. State of Alaska Department of Revenue purchased a new stake in shares of MiniMed Group in the 3rd quarter worth about $227,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of MiniMed Group in the 2nd quarter worth about $185,000.

MiniMed Group Trading Up 5.1%

Shares of MMED stock opened at $18.25 on Thursday. The company has a market capitalization of $5.13 billion and a price-to-earnings ratio of -26.84. The firm has a 50-day moving average price of $19.84 and a 200 day moving average price of $16.71. MiniMed Group Inc has a twelve month low of $10.65 and a twelve month high of $24.43.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. BTIG Research lifted their target price on shares of MiniMed Group from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, September 1st. Truist Financial began coverage on shares of MiniMed Group in a report on Thursday, September 24th. They issued a “buy” rating and a $29.00 price target on the stock. Bank of America increased their price target on shares of MiniMed Group from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, September 2nd. Mizuho lifted their price objective on MiniMed Group from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, October 8th. Finally, UBS Group upped their target price on MiniMed Group from $25.00 to $28.00 and gave the company a “buy” rating in a research note on Wednesday, September 2nd. Fourteen research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $24.25.

About MiniMed Group

MiniMed Group focuses on diabetes technology, developing products and services to help people manage insulin-dependent diabetes. Its offerings include insulin pumps, continuous glucose monitoring systems, infusion sets and software for tracking glucose and coordinating insulin delivery. The business is known for automated insulin-delivery systems that use glucose readings to help adjust insulin delivery, including products in the MiniMed 780G system line. Its technologies are intended for use by people with diabetes and the clinicians who support their care.